Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1068P is a processed pseudogene derived from the U6 small nuclear RNA (snRNA) gene family. U6 snRNA itself is a highly conserved, non-coding RNA that plays a central role as a catalytic component of the spliceosome, where it functions in removing introns from pre-mRNA during splicing[3][1]. However, RNU6-1068P carries sequence similarity to U6 snRNA but is non-functional—lacking essential regulatory or structural elements required for normal RNA maturation, splicing machinery assembly, or activity[2]. Pseudogenes like RNU6-1068P arise through retrotransposition (typically via LINE-1 elements) or gene duplication followed by loss of function, and serve as genomic markers of retrotransposon activity in the genome, but do not participate in canonical molecular or cellular processes[2]. Their presence does not typically have direct therapeutic implications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1068, pseudogene (RNU6-1068P).